Tetraphase Pharmaceuticals Inc (TTPH) Expected to Post Earnings of -$0.39 Per Share

Wall Street brokerages forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will announce earnings per share (EPS) of ($0.39) for the current quarter, Zacks reports. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.28). Tetraphase Pharmaceuticals reported earnings of ($0.42) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The firm is expected to announce its next earnings results on Thursday, May 2nd.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.78) to ($1.23). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.68) to ($0.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.40). The firm had revenue of $4.28 million during the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 381.71% and a negative return on equity of 72.26%.

A number of equities analysts have weighed in on TTPH shares. Robert W. Baird reiterated a “buy” rating and set a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, January 7th. B. Riley started coverage on shares of Tetraphase Pharmaceuticals in a research report on Friday, January 4th. They set a “buy” rating and a $3.00 target price for the company. Gabelli lowered shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 target price for the company. in a research report on Friday, March 15th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Finally, Piper Jaffray Companies cut their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $4.09.

NASDAQ:TTPH traded up $0.14 on Friday, reaching $1.34. 1,266,539 shares of the company’s stock were exchanged, compared to its average volume of 679,173. The company has a quick ratio of 7.73, a current ratio of 7.78 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $64.49 million, a PE ratio of -0.98 and a beta of 2.99. Tetraphase Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $4.49.

Several hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Tetraphase Pharmaceuticals by 6.4% in the fourth quarter. Bank of America Corp DE now owns 142,775 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 8,567 shares during the period. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% in the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 15,000 shares during the period. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% in the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 21,089 shares during the period. Geode Capital Management LLC boosted its position in shares of Tetraphase Pharmaceuticals by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 551,837 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 21,854 shares during the period. Finally, Alambic Investment Management L.P. raised its stake in Tetraphase Pharmaceuticals by 31.0% in the fourth quarter. Alambic Investment Management L.P. now owns 114,874 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 27,170 shares in the last quarter. Institutional investors own 44.02% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: How is Preferred Stock Different from Common Stock?

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.